336 related articles for article (PubMed ID: 33002095)
1. STAT3 imparts BRCAness by impairing homologous recombination repair in Epstein-Barr virus-transformed B lymphocytes.
McIntosh MT; Koganti S; Boatwright JL; Li X; Spadaro SV; Brantly AC; Ayers JB; Perez RD; Burton EM; Burgula S; MacCarthy T; Bhaduri-McIntosh S
PLoS Pathog; 2020 Oct; 16(10):e1008849. PubMed ID: 33002095
[TBL] [Abstract][Full Text] [Related]
2. STAT3 interrupts ATR-Chk1 signaling to allow oncovirus-mediated cell proliferation.
Koganti S; Hui-Yuen J; McAllister S; Gardner B; Grasser F; Palendira U; Tangye SG; Freeman AF; Bhaduri-McIntosh S
Proc Natl Acad Sci U S A; 2014 Apr; 111(13):4946-51. PubMed ID: 24639502
[TBL] [Abstract][Full Text] [Related]
3. Novel replisome-associated proteins at cellular replication forks in EBV-transformed B lymphocytes.
Xu H; Perez RD; Frey TR; Burton EM; Mannemuddhu S; Haley JD; McIntosh MT; Bhaduri-McIntosh S
PLoS Pathog; 2019 Dec; 15(12):e1008228. PubMed ID: 31841561
[TBL] [Abstract][Full Text] [Related]
4. Cellular STAT3 functions via PCBP2 to restrain Epstein-Barr Virus lytic activation in B lymphocytes.
Koganti S; Clark C; Zhi J; Li X; Chen EI; Chakrabortty S; Hill ER; Bhaduri-McIntosh S
J Virol; 2015 May; 89(9):5002-11. PubMed ID: 25717101
[TBL] [Abstract][Full Text] [Related]
5. A role for human homologous recombination factors in suppressing microhomology-mediated end joining.
Ahrabi S; Sarkar S; Pfister SX; Pirovano G; Higgins GS; Porter AC; Humphrey TC
Nucleic Acids Res; 2016 Jul; 44(12):5743-57. PubMed ID: 27131361
[TBL] [Abstract][Full Text] [Related]
6. Microhomology-mediated end joining: Good, bad and ugly.
Seol JH; Shim EY; Lee SE
Mutat Res; 2018 May; 809():81-87. PubMed ID: 28754468
[TBL] [Abstract][Full Text] [Related]
7. B lymphocytes from patients with a hypomorphic mutation in STAT3 resist Epstein-Barr virus-driven cell proliferation.
Koganti S; de la Paz A; Freeman AF; Bhaduri-McIntosh S
J Virol; 2014 Jan; 88(1):516-24. PubMed ID: 24173212
[TBL] [Abstract][Full Text] [Related]
8. Interplay between the Epigenetic Enzyme Lysine (K)-Specific Demethylase 2B and Epstein-Barr Virus Infection.
Vargas-Ayala RC; Jay A; Manara F; Maroui MA; Hernandez-Vargas H; Diederichs A; Robitaille A; Sirand C; Ceraolo MG; Romero-Medina MC; Cros MP; Cuenin C; Durand G; Le Calvez-Kelm F; Mundo L; Leoncini L; Manet E; Herceg Z; Gruffat H; Accardi R
J Virol; 2019 Jul; 93(13):. PubMed ID: 30996097
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr Virus Latent Membrane Protein 2A (LMP2A) enhances IL-10 production through the activation of Bruton's tyrosine kinase and STAT3.
Incrocci R; Barse L; Stone A; Vagvala S; Montesano M; Subramaniam V; Swanson-Mungerson M
Virology; 2017 Jan; 500():96-102. PubMed ID: 27792904
[TBL] [Abstract][Full Text] [Related]
10. p62-mediated Selective autophagy endows virus-transformed cells with insusceptibility to DNA damage under oxidative stress.
Wang L; Howell MEA; Sparks-Wallace A; Hawkins C; Nicksic CA; Kohne C; Hall KH; Moorman JP; Yao ZQ; Ning S
PLoS Pathog; 2019 Apr; 15(4):e1007541. PubMed ID: 31017975
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus-associated lymphoproliferative disorders.
Grywalska E; Markowicz J; Grabarczyk P; Pasiarski M; Roliński J
Postepy Hig Med Dosw (Online); 2013 May; 67():481-90. PubMed ID: 23752600
[TBL] [Abstract][Full Text] [Related]
12. Activation of EHF via STAT3 phosphorylation by LMP2A in Epstein-Barr virus-positive gastric cancer.
Li W; Okabe A; Usui G; Fukuyo M; Matsusaka K; Rahmutulla B; Mano Y; Hoshii T; Funata S; Hiura N; Fukayama M; Tan P; Ushiku T; Kaneda A
Cancer Sci; 2021 Aug; 112(8):3349-3362. PubMed ID: 34014591
[TBL] [Abstract][Full Text] [Related]
13. STAT3 activates the anti-apoptotic form of caspase 9 in oncovirus-infected B lymphocytes.
Koganti S; Burgula S; Bhaduri-McIntosh S
Virology; 2020 Jan; 540():160-164. PubMed ID: 31928997
[TBL] [Abstract][Full Text] [Related]
14. Dominant-negative derivative of EBNA1 represses EBNA1-mediated transforming gene expression during the acute phase of Epstein-Barr virus infection independent of rapid loss of viral genome.
Kariya Y; Hamatake M; Urano E; Yoshiyama H; Shimizu N; Komano J
Cancer Sci; 2010 Apr; 101(4):876-81. PubMed ID: 20132216
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr Virus Induced Cytidine Metabolism Roles in Transformed B-Cell Growth and Survival.
Liang JH; Wang C; Yiu SPT; Zhao B; Guo R; Gewurz BE
mBio; 2021 Aug; 12(4):e0153021. PubMed ID: 34281398
[TBL] [Abstract][Full Text] [Related]
16. Early gene expression changes by Epstein-Barr virus infection of B-cells indicate CDKs and survivin as therapeutic targets for post-transplant lymphoproliferative diseases.
Bernasconi M; Ueda S; Krukowski P; Bornhauser BC; Ladell K; Dorner M; Sigrist JA; Campidelli C; Aslandogmus R; Alessi D; Berger C; Pileri SA; Speck RF; Nadal D
Int J Cancer; 2013 Nov; 133(10):2341-50. PubMed ID: 23640782
[TBL] [Abstract][Full Text] [Related]
17. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies.
Westphal EM; Blackstock W; Feng W; Israel B; Kenney SC
Cancer Res; 2000 Oct; 60(20):5781-8. PubMed ID: 11059774
[TBL] [Abstract][Full Text] [Related]
18. STAT3 activation contributes directly to Epstein-Barr virus-mediated invasiveness of nasopharyngeal cancer cells in vitro.
Lui VW; Wong EY; Ho Y; Hong B; Wong SC; Tao Q; Choi GC; Au TC; Ho K; Yau DM; Ma BB; Hui EP; Chan AS; Tsang CM; Tsao SW; Grandis JR; Chan AT
Int J Cancer; 2009 Oct; 125(8):1884-93. PubMed ID: 19588483
[TBL] [Abstract][Full Text] [Related]
19. Comparative proteomic analysis implicates COMMD proteins as Epstein-Barr virus targets in the BL41 Burkitt's lymphoma cell line.
Gkiafi Z; Panayotou G
J Proteome Res; 2011 Jul; 10(7):2959-68. PubMed ID: 21615174
[TBL] [Abstract][Full Text] [Related]
20. Current Trends and Alternative Scenarios in EBV Research.
Minarovits J; Niller HH
Methods Mol Biol; 2017; 1532():1-32. PubMed ID: 27873264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
